Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth.

Jiménez AP, Traum A, Boettger T, Hackstein H, Richter AM, Dammann RH.

Oncotarget. 2017 May 23;8(51):88437-88452. doi: 10.18632/oncotarget.18177. eCollection 2017 Oct 24.

2.

Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer.

Dammann RH, Richter AM, Jiménez AP, Woods M, Küster M, Witharana C.

Int J Mol Sci. 2017 Oct 17;18(10). pii: E2160. doi: 10.3390/ijms18102160. Review.

3.

ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer.

Richter AM, Kiehl S, Köger N, Breuer J, Stiewe T, Dammann RH.

Clin Epigenetics. 2017 Jun 2;9:60. doi: 10.1186/s13148-017-0360-4. eCollection 2017.

4.

Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer.

Richter AM, Walesch SK, Dammann RH.

Cancers (Basel). 2016 Feb 25;8(3). pii: E26. doi: 10.3390/cancers8030026.

5.

The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms.

Haag T, Richter AM, Schneider MB, Jiménez AP, Dammann RH.

BMC Cancer. 2016 Feb 1;16:49. doi: 10.1186/s12885-016-2087-6.

6.

Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi.

Walesch SK, Richter AM, Helmbold P, Dammann RH.

Cancers (Basel). 2015 Jul 7;7(3):1233-43. doi: 10.3390/cancers7030834.

7.

Promoter methylation status of Ras-association domain family members in pheochromocytoma.

Richter AM, Zimmermann T, Haag T, Walesch SK, Dammann RH.

Front Endocrinol (Lausanne). 2015 Feb 19;6:21. doi: 10.3389/fendo.2015.00021. eCollection 2015.

8.

ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth.

Kiehl S, Herkt SC, Richter AM, Fuhrmann L, El-Nikhely N, Seeger W, Savai R, Dammann RH.

Sci Rep. 2014 Nov 4;4:6899. doi: 10.1038/srep06899.

9.
10.

Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma.

Richter AM, Haag T, Walesch S, Herrmann-Trost P, Marsch WC, Kutzner H, Helmbold P, Dammann RH.

Cancers (Basel). 2013 Nov 18;5(4):1566-76. doi: 10.3390/cancers5041566.

11.

The SARAH Domain of RASSF1A and Its Tumor Suppressor Function.

Dittfeld C, Richter AM, Steinmann K, Klagge-Ulonska A, Dammann RH.

Mol Biol Int. 2012;2012:196715. doi: 10.1155/2012/196715. Epub 2012 Apr 9.

12.

RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.

Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WCh, Enk A, Dammann RH.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):687-94. doi: 10.1038/jid.2011.380. Epub 2011 Nov 24.

13.

Epigenetic silencing of erythropoietin in human cancers.

Steinmann K, Richter AM, Dammann RH.

Genes Cancer. 2011 Jan;2(1):65-73. doi: 10.1177/1947601911405043.

14.

Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.

Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH.

Mol Cancer. 2010 Sep 29;9:264. doi: 10.1186/1476-4598-9-264.

15.

Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function.

Richter AM, Schagdarsurengin U, Rastetter M, Steinmann K, Dammann RH.

Eur J Cancer. 2010 Nov;46(16):2986-95. doi: 10.1016/j.ejca.2010.06.128. Epub 2010 Jul 23.

PMID:
20655196
16.

Frequent epigenetic inactivation of RASSF10 in thyroid cancer.

Schagdarsurengin U, Richter AM, Wöhler C, Dammann RH.

Epigenetics. 2009 Nov 16;4(8):571-6. Epub 2009 Nov 14.

PMID:
19934646
17.

The RASSF proteins in cancer; from epigenetic silencing to functional characterization.

Richter AM, Pfeifer GP, Dammann RH.

Biochim Biophys Acta. 2009 Dec;1796(2):114-28. doi: 10.1016/j.bbcan.2009.03.004. Epub 2009 Mar 31. Review.

PMID:
19344752

Supplemental Content

Loading ...
Support Center